Diabetic Retinopathy is an eye condition that can cause vision problems in people with diabetes. This study is testing a new drug called tarcocimab to see if it works better than a fake treatment (sham) for people with a serious type of this condition called non-proliferative diabetic retinopathy (NPDR). The study lasts 48 weeks, and participants will be observed to see if their eye condition improves.

People with Type 1 or Type 2 diabetes can join if they have not had certain eye treatments before. They must also have a stable blood sugar level, measured by a test called HbA1c. Other eye conditions or recent serious health problems might prevent someone from joining.

• The study lasts for about one year with regular check-ups.
• Participants must have diabetes and a certain level of eye health.
• There are no previous eye treatments allowed for eligibility.

Participants who qualify will receive either the tarcocimab or a sham treatment to see if their eye health improves.